Bernard A. Fox, Co-founder, President, and CEO of UbiVac, shared a post on LinkedIn:
“Great being at JPM2026 and having chance to catch-up with friends at Parker Institute for Cancer Immunotherapy reception and talk about what excites people.
For me it is easy! Dark Genome-derived cancer’s Dark Matter and UbiVac’s 1st-in-class Dark Matter immunotherapy.
Combination immunotherapy with DPV001, an ‘off-the-shelf’ Cancer Vaccine – designed as treatment for the spectrum of cancers – and containing more than 400 Dark Matter non-canonical antigens plus 300 canonical proteins for genes over-expressed by cancers of the lung, breast, prostate, pancreas, stomach, ovary, brain, and head and neck – has tripled response rates and CR rates over historical anti-PD-1 alone in patients with advanced/recurrent HNSCC.
Watch for invited review in Journal for ImmunoTherapy of Cancer due out soon..
With collaborators at Earle A. Chiles Research Institute / Providence Cancer Institute we are in discovery mode characterizing unique targets and figuring how to move a 56%RR to 80% or 90%. To do more with dark matter discovery and to expand clinical data we need investors and/or pharma collaborators..
That’s why I am at JPM.”
More posts featuring Bernard A. Fox.
